Prevalence of serum neutralizing antibodies to adenovirus type 5 (Ad5) and 41 (Ad41) in children is associated with age and sanitary conditions

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Susan Buchbinder, Devan V. Mehrotra, Ann Duerr et al. · The Lancet · 2008 · 1.7K citations · Full text

Vaccination, Test-of-concept Trial, Treatment And Prevention +11

Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D

Peter Abbink, Angelique A. C. Lemckert, Bonnie A. Ewald et al. · Journal of Virology · 2007 · 503 citations · Full text

International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations

Dan H. Barouch, Sandra V. Kik, Gerrit Jan Weverling et al. · Vaccine · 2011 · 302 citations

Diagnostic Virology, Viral Diagnostics, International Seroepidemiology +5

International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials

T. Christopher Mast, Lisa Kierstead, Swati B. Gupta et al. · Vaccine · 2009 · 276 citations

Vaccination, Viral Diagnostics, Human Retrovirus +10

A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults

Julie E. Ledgerwood, Pamela Costner, Niraj M. Desai et al. · Vaccine · 2010 · 208 citations

Vaccination, Vaccine Development, Immunology +6